Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ovarian cancer (OC) and
endometrial cancer
(EC) are two types of the most frequent gynecological malignancies worldwide. However, the prognosis of OC and EC patients remained gloomy. Therefore, there was still an urgent need to identify new biomarkers for early diagnosis and treatment of OC and EC. TCGA datasets were used to screen the
KLHL14
expression levels in 18 different types of human cancers. TCGA datasets were also used to analyze the association between
KLHL14
expression levels and OS/PFS in OC and EC. Human Protein Atlas was used to detected the KLHL14 protein levels in OC and EC. Kaplan-Meier plotter was used to evaluate the prognostic values of
KLHL14
in Ovarian cancer. MAS 3.0 was used to perform GO and KEGG pathway analysis. STRING was used to perform PPI network.
KLHL14
was specially expressed in OC and EC samples. Moreover,
KLHL14
was found to be up-regulated in all stage of OC and EC samples. By analyzing Kaplan-Meier plotter and TCGA datasets, we found higher
KLHL14
expression level was associated with shorter overall and progression-free survival in both OC and EC patients. Furthermore, GO and KEGG analysis of
KLHL14
co-expressing genes indicated it played important roles in OC and EC progression. We for the first time reported
KLHL14
was specially over-expressed in ovarian and
endometrial cancer
, up-regulation of
KLHL14
was positively associated with worse outcome. Finally, we found knockdown of
KLHL14
suppressed OC cell proliferation.
KLHL14
could be a potential biomarker and therapy target for OC and EC.
...
PMID:KLHL14, an ovarian and endometrial-specific gene, is over-expressed in ovarian and endometrial cancer. 3223 3